» Articles » PMID: 30901907

Global Epidemiology of Mucormycosis

Overview
Journal J Fungi (Basel)
Date 2019 Mar 24
PMID 30901907
Citations 352
Authors
Affiliations
Soon will be listed here.
Abstract

Mucormycosis is an angio-invasive fungal infection, associated with high morbidity and mortality. A change in the epidemiology of mucormycosis has been observed in recent years with the rise in incidence, new causative agents and susceptible population. The rise has been perceived globally, but it is very high in the Asian continent. Though diabetes mellitus overshadow all other risk factors in Asia, post-tuberculosis and chronic renal failure have emerged as new risk groups. The rhino-cerebral form of mucormycosis is most commonly seen in patients with diabetes mellitus, whereas, pulmonary mucormycosis in patients with haematological malignancy and transplant recipients. In immunocompetent hosts, cutaneous mucormycosis is commonly seen following trauma. The intriguing clinical entity, isolated renal mucormycosis in immunocompetent patients is only reported from China and India. A new clinical entity, indolent mucormycosis in nasal sinuses, is recently recognized. The causative agents of mucormycosis vary across different geographic locations. Though is the most common agent isolated worldwide, is predominant in Asia and species in Europe. The new causative agents, , , and are reported from Asia. In conclusion, with the change in epidemiology of mucormycosis country-wise studies are warranted to estimate disease burden in different risk groups, analyse the clinical disease pattern and identify the new etiological agents.

Citing Articles

Arora-Nagarkar Prognostic Classification for Rhinocerebral Mucormycosis: A Novel Prognostic Classification System.

Arora R, Aggarwal A, Nagarkar N, Thangaraju P, Keche A, Bodhey N Indian J Otolaryngol Head Neck Surg. 2025; 77(1):412-416.

PMID: 40066399 PMC: 11890712. DOI: 10.1007/s12070-024-05210-9.


Invasive Fungal Disease After Chimeric Antigen Receptor-T Immunotherapy in Adult and Pediatric Patients.

Evangelidis P, Tragiannidis K, Vyzantiadis A, Evangelidis N, Kalmoukos P, Vyzantiadis T Pathogens. 2025; 14(2).

PMID: 40005545 PMC: 11858289. DOI: 10.3390/pathogens14020170.


[Diagnosis of mucormycosis in three children following hematopoietic stem cell transplantation using metagenomic next-generation sequencing].

Li Y, Zhou X, Wang X, Wang C, Cao K, Liu S Zhongguo Dang Dai Er Ke Za Zhi. 2025; 27(2):219-224.

PMID: 39962786 PMC: 11838025. DOI: 10.7499/j.issn.1008-8830.2408034.


Appendiceal Perforation and Abdominal Wall Infection Caused by Invasive Mucormycosis in a Child with Acute Leukemia.

Li C, Luo Y, Wang Y, Bai Q Infect Drug Resist. 2025; 18:495-498.

PMID: 39898350 PMC: 11784252. DOI: 10.2147/IDR.S504206.


Real-World Effectiveness and Safety of Isavuconazole Versus Amphotericin B for Patients with Invasive Mucormycosis.

Qin J, Bi H, Tang G, Liu X, Qu J, Lv X Microorganisms. 2025; 13(1).

PMID: 39858823 PMC: 11767576. DOI: 10.3390/microorganisms13010055.


References
1.
Yamazaki T, Kume H, Murase S, Yamashita E, Arisawa M . Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan. J Clin Microbiol. 1999; 37(6):1732-8. PMC: 84937. DOI: 10.1128/JCM.37.6.1732-1738.1999. View

2.
Lee F, Mossad S, Adal K . Pulmonary mucormycosis: the last 30 years. Arch Intern Med. 1999; 159(12):1301-9. DOI: 10.1001/archinte.159.12.1301. View

3.
Ribes J, Baker D . Zygomycetes in human disease. Clin Microbiol Rev. 2001; 13(2):236-301. PMC: 100153. DOI: 10.1128/CMR.13.2.236. View

4.
Chakrabarti A, Das A, Sharma A, Panda N, Das S, Gupta K . Ten years' experience in zygomycosis at a tertiary care centre in India. J Infect. 2001; 42(4):261-6. DOI: 10.1053/jinf.2001.0831. View

5.
Alsuwaida K . Primary cutaneous mucormycosis complicating the use of adhesive tape to secure the endotracheal tube. Can J Anaesth. 2002; 49(8):880-2. DOI: 10.1007/BF03017426. View